AMT to Release Full Year 2008 Results on February 24, 2009
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of
human gene therapy, announced today that it will release its financial
results for the full year 2008 on
Central European Time (CET). To discuss these results, the Company will
conduct a conference call that day at
The dial-in number for
number for
+44-207-107-0611 and for the rest of
the
via the internet, visit the investor relations portion of the AMT website at
http://www.amtbiopharma.com. Please go to the website fifteen minutes prior
to the call to register, download and install the necessary audio software.
About Amsterdam Molecular Therapeutics
AMT has a unique gene therapy platform that to date appears to circumvent
many if not all of the obstacles that have prevented gene therapy from
becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV)
vectors as the delivery vehicle of choice for therapeutic genes, the company
has been able to design and validate what is probably the first stable and
scalable AAV GMP production platform. As such, AMT’s proprietary platform
holds tremendous promise for thousands of (rare) diseases that are caused by
one faulty gene. AMT currently has a product pipeline with nine products at
different stages of development.
Certain statements in this press release are “forward-looking statements”
including those that refer to management’s plans and expectations for future
operations, prospects and financial condition. Words such as “strategy,”
“expects,” “plans,” “anticipates,” “believes,” “will,” “continues,”
“estimates,” “intends,” “projects,” “goals,” “targets” and other words of
similar meaning are intended to identify such forward-looking statements.
Such statements are based on the current expectations of the management of
Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on
these statements because, by their nature, they are subject to known and
unknown risks and can be affected by factors that are beyond the control of
AMT. Actual results could differ materially from current expectations due to
a number of factors and uncertainties affecting AMT’s business, including,
but not limited to, the timely commencement and success of AMT’s clinical
trials and research endeavors, delays in receiving U.S. Food and Drug
Administration or other regulatory approvals (i.e. EMEA, Health Canada),
market acceptance of AMT’s products, effectiveness of AMT’s marketing and
sales efforts, development of competing therapies and/or technologies, the
terms of any future strategic alliances, the need for additional capital, the
inability to obtain, or meet, conditions imposed for required governmental
and regulatory approvals and consents. AMT expressly disclaims any intent or
obligation to update these forward-looking statements except as required by
law. For a more detailed description of the risk factors and uncertainties
affecting AMT, refer to the prospectus of AMT’s initial public offering on
SOURCE Amsterdam Molecular Therapeutics B.V